

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-4. (canceled).

5. (currently amended): A method for treating a CCR4-expressing tumor in a patient, comprising administering to said patient a recombinant antibody or antigen-binding fragment thereof which specifically binds to human CC chemokine receptor 4 (CCR4), and at least one agent, wherein said agent is not conjugated to said antibody or antigen-binding fragment.

6. (previously presented): The method according to claim 5, wherein said CCR4-expressing tumor is a hematopoietic organ tumor.

7-26. (canceled).

27. (previously presented): The method according to claim 5, wherein said recombinant antibody or antigen-binding fragment thereof which specifically binds to CCR4 specifically binds to an extracellular region of CCR4 and does not show a reactivity to a human platelet.

28. (previously presented): The method according to claim 27, wherein said recombinant antibody or antigen-binding fragment thereof which specifically binds to the extracellular region of CCR4 does not have an activity of inhibiting binding of thymus and activation-regulated chemokine (TARC) or macrophage-derived chemokine (MDC) as a CCR4 ligand to CCR4.

29. (previously presented): The method according to claim 28, wherein said extracellular region is an extracellular region selected from the group consisting of positions 1 to 39, 98 to 112, 176 to 206 and 271 to 284 of the amino acid sequence as set forth in SEQ ID NO: 1.

30. (previously presented): The method according to claim 28, wherein said extracellular region is an epitope consisting of positions 2 to 29 of the amino acid sequence as set forth in SEQ ID NO: 1.

31. (previously presented): The method according to claim 28, wherein said extracellular region is an epitope consisting of positions 13 to 29 of the amino acid sequence as set forth in SEQ ID NO: 1.

32. (previously presented): The method according to claim 28, wherein said extracellular region is an epitope consisting of positions 13 to 25 of the amino acid sequence as set forth in SEQ ID NO: 1.

33. (previously presented): The method according to claim 32, wherein said recombinant antibody or antigen-binding fragment thereof which specifically binds to the extracellular region of CCR4 has a binding activity to a polypeptide comprising amino acids 13 to 25 of SEQ ID NO: 1, in which at least one of tyrosine residues 16, 19, 20 and 22 is sulfated, which is lower than a binding activity to a peptide comprising amino acids 13 to 25 of SEQ ID NO: 1.

34. (previously presented): The method according to claim 33, wherein said recombinant antibody or antigen-binding fragment thereof which specifically binds to the extracellular region of CCR4 specifically reacts with an epitope specifically bound by a monoclonal antibody produced by hybridoma KM 2160 (FERM BP-10090).

35. (previously presented): The method according to claim 34, wherein said recombinant antibody is a human chimeric antibody or a human CDR-grafted antibody.

36. (previously presented): The method according to claim 35, wherein said human chimeric antibody comprises complementarity determining regions (CDRs) of a heavy chain (H chain) variable region (V region) and a light chain (L chain) V region of a monoclonal antibody which specifically binds to CCR4.

37. (currently amended): The method according to claim 36, wherein said human chimeric antibody comprises CDR1, CDR2 and CDR3 domains of a heavy chain (H chain) variable region (V region) comprising the amino acid sequences as set forth in SEQ ID NOs: 5,

6 and 7, respectively, ~~and/or~~and CDR1, CDR2 and CDR3 domains of a light chain (L chain) variable region (V region) comprising the amino acid sequences as set forth in SEQ ID NOs: 8, 9 and 10, respectively.

38. (currently amended): The method according to claim 37, wherein said human chimeric antibody comprises a heavy chain (H chain) variable region (V region) comprising the amino acid sequence as set forth in SEQ ID NO: 11, ~~and/or~~and a light chain (L chain) V region of an antibody molecule comprising the amino acid sequence as set forth in SEQ ID NO: 12.

39. (previously presented): The method according to claim 35, wherein said human CDR-grafted antibody comprises complementarity determining regions (CDRs) of a heavy chain (H chain) variable region (V region) and a light chain (L chain) V region of a monoclonal antibody which specifically binds to CCR4.

40. (currently amended): The method according to claim 39, wherein said human CDR-grafted antibody comprises CDR1, CDR2 and CDR3 domains of a heavy chain (H chain) variable region (V region) comprising the amino acid sequences as set forth in SEQ ID NOs: 5, 6 and 7, respectively, ~~and/or~~and CDR1, CDR2 and CDR3 domains of a light chain (L chain) variable region (V region) comprising the amino acid sequences as set forth in SEQ ID NOs: 8, 9 and 10, respectively.

41. (currently amended): The method according to claim 40, wherein the human CDR-grafted antibody comprises a heavy chain (H chain) variable region (V region) comprising

the amino acid sequence as set forth in SEQ ID NO: 16 or 17, ~~and/or~~ and a light chain (L chain) V region of an antibody molecule comprising the amino acid sequence as set forth in SEQ ID NO: 18.

42. (previously presented): The method according to claim 5, wherein the agent is a protein or an agent having a low-molecular weight.

43. (previously presented): The method according to claim 42, wherein said protein is a cytokine or an antibody.

44. (previously presented): The method according to claim 43, wherein said cytokine is a cytokine selected from the group consisting of G-CSF, M-CSF, interferon- α , IL-2 and IL-15.

45. (currently amended): The method according to ~~claim 44~~ claim 42, wherein said agent having a low-molecular weight is a chemotherapeutic agent or a hormone therapeutic agent.

46. (previously presented): The method according to claim 45, wherein said chemotherapeutic agent is an agent selected from the group consisting of vincristine, cyclophosphamide, etoposide and Methotrexate.